CD73-IN-14

Cat. No.:	HY-152074
CAS No.:	2407356-67-4
Molecular Formula:	$C_{26}H_{26}ClN_7O_9$
Molecular Weight:	615.98
Target:	CD73
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

D73-IN-14 is a potent, selective and orally active CD73 inhibitor with an IC_{50} value of 0.17 nM. CD73-IN-14 increases the number of tumor-infiltrating $CD8^+$ cells and shows anti-tumor activity[1]. CD73-IN-14 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

IC_{50} & Target

C_{50}: 0.17 nM (CD73)[1]

In Vivo

CD73-IN-14 (10, 25, 50 mg/kg; p.o.; twice-a-day for 20 days) shows anti-tumor activity in mouse[1].br/>Pharmacokinetic Parameters of CD73-IN-14 in rats[1].

PO Dose (mg/kg)	$AUC_{0\text{-}24\ h}$ (ng*hr/mL)	C_{max}(nM)	T_{max}(hr)
50	580	74	0.8
200	6094	1800	0.8
500	18500	11000	0.3

rats, 50, 200, 500 mg/kg p.o.[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 mice (EG7 model)[1]
Dosage:	10, 25, 50 mg/kg
Administration:	P.o.; twice a day for 20 days
Result:	Increased tumor-infiltrating CD8+ cells and decreased the tumor volume in a dose dependet manner.

REFERENCES

[1]. Li J, et al. Discovery of a Series of Potent, Selective, and Orally Bioavailable Nucleoside Inhibitors of CD73 That Demonstrates In Vivo Antitumor Activity. J Med Chem. 2022 Dec 18.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA